Trial Profile

Phase 1/2, Open-label Study Evaluating Safety of Repeat Administration of Ad/PNP-F-araAMP (Ad/PNP Administered Intratumorally Followed by Intravenous Fludarabine Phosphate) in Subjects With Recurrent, Local Head and Neck Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Purine nucleoside phosphorylase (Primary) ; Fludarabine
Indications Head and neck cancer; Nasopharyngeal cancer; Pharyngeal neoplasms; Salivary gland cancer; Squamous cell cancer; Tongue cancer
Focus Adverse reactions; Registrational
Sponsors GeoVax Labs

30 Apr 2025 Results evaluating the safety of repeat administration of a dose level of Ad/PNP plus fludarabine phosphate (F-araAMP) presented at the 116th Annual Meeting of the American Association for Cancer Research.
04 Mar 2025 Status changed from active, no longer recruiting to completed.
24 Oct 2024 Planned End Date changed from 1 Aug 2025 to 1 Dec 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com